FIG. 1.

Median percent change in triglycerides (A), total cholesterol (B), LDL cholesterol (C), and HDL cholesterol (D), and median change in total-to-HDL cholesterol ratio (E) at different time points during the study. Black squares denote abacavir/lamivudine, and white squares denote tenofovir/emtricitabine. Continuous lines denote raltegravir, and dashed lines denote ritonavir-boosted protease inhibitors. p-values within the dashed lines refer to comparisons between ritonavir-boosted protease inhibitor (PI/r)-containing regimens and p-values within the continuous lines refer to comparisons between raltegravir (RAL)-containing regimens at different time points.